Diverse customer base entrusts WorldCare Clinical with studies across therapeutic areas
Boston, MA, January 15, 2015 –WorldCare Clinical, the premier provider of imaging services to the pharmaceutical and biotechnology industry, today announced its sales of services increased more than 150% in 2014 over the prior year. The sales growth was across a diverse customer base and includes new study wins in the Oncology, Neurology, Musculoskeletal, and Cardiovascular therapeutic areas.
"Sponsors are seeking therapeutic-area-experience and scientific expertise, as well as operational excellence," stated Aaron Timm, CEO of WorldCare Clinical. "In addition, our financial strength and operational stability are attractive to clients looking for a long-term partner for their global trials. We appreciate the trust that sponsors have placed in us, and our team will continue to focus every day on delivering outstanding service."
About WorldCare Clinical
WorldCare Clinical is a global imaging CRO that employs scientific expertise, innovative technology, and operational excellence to maximize the precision and accuracy of a blinded independent central review of Phase I – IV clinical trial data. The company has worked with thousands of sites in more than 60 countries. WCC’s robust technology platform processes over 250 million images annually (CT, MRI, X-Ray, Echo, US, PET). Originally founded in 1992 by the Massachusetts General Hospital (MGH) Department of Radiology, WorldCare continues to maintain a strategic relationship with the Harvard Hospital System as well as other leading academic institutions.
For more information on WCC's services, please visit our website at wcclinical.com. or contact: